A High Number With No Symptoms: Treating Hyperuricemia Before the First Flare
A single patient, never having had a gout flare, has a very high urate found incidentally on labs drawn for something else. The disagreement is whether a number that high, in a patient this specific, is still just a number.
Aaron P., a 41-year-old accountant training for his first marathon, came in for low back pain after a long training run, and the CT scan ordered to rule out a stress-related process instead found a 4mm non-obstructing stone in his right kidney, composed — on later analysis after he passed it spontaneously — of pure uric acid. He has never had a gout flare, has no joint symptoms of any kind, and was startled to learn that the same basic metabolic panel drawn that day showed a serum urate of 10.4 mg/dL, well above the solubility threshold where crystals form. His father and paternal uncle both developed gout in their fifties, and his father has had two uric acid stones himself — a family pattern Aaron had never connected to anything before this visit, having spent most of his adult life assuming his only inherited cardiovascular risk worth tracking was his mother's side, where two aunts had early heart disease.
The number alone would not usually prompt treatment. Both the ACR and EULAR gout guidelines explicitly recommend against starting urate-lowering therapy for asymptomatic hyperuricemia in general, reasoning that the evidence for benefit is thin and the harms of lifelong medication are real, even though a higher urate does statistically raise future gout risk. The strongest test of a renal-protection argument for early treatment, the PERL trial, randomized patients with type 1 diabetes and early diabetic kidney disease to allopurinol or placebo specifically to see whether lowering urate would slow GFR decline — and found no benefit, despite a plausible epidemiologic association between higher urate and faster kidney function loss. Aaron doesn't have diabetes, so PERL doesn't even directly address him; what he does have is a uric acid stone already formed, a strong family history, and a number nearly double the treatment target used once gout is diagnosed.
A stone, a number, and no joint disease yet
The guideline recommendation against treating asymptomatic hyperuricemia is aimed at a high number with no disease event attached to it. He has a confirmed uric acid stone. That's urate disease, even without a joint ever having flared — I'd read him as already past the "asymptomatic" line the guideline is actually drawing, not as an exception carved out of it.
I'd be careful extending that logic too far. PERL randomized patients with diabetic kidney disease specifically to test whether lowering urate protects kidney function, on the strength of exactly this kind of "the number itself is the disease" reasoning — and found no benefit, despite a real epidemiologic association going in. It's a different population than Aaron's, but it's a direct test of the same underlying instinct, and it came back negative. That should make us slower to commit a 41-year-old with normal kidneys to lifelong medication on one stone and one lab value.
A single stone is a real event, I agree — but PERL is a reminder that "urate caused this, so lowering urate will help" doesn't hold up every time it's tested directly.
Before either side acts on their position, there's an intervention neither of you has mentioned that addresses the stone's own mechanism directly: he runs long distances with low fluid intake, which concentrates his urine exactly the way uric acid stones form. Aggressive hydration and dietary moderation, with repeat urate and a 24-hour urine study in a few months, costs him nothing and might answer whether this was a one-time event or a genuine pattern before anyone commits to a lifelong drug.
Agreed: hydration and dietary counseling started now, with repeat labs and a urine study in three months, and allopurinol held rather than started or formally ruled out. All three voices accepted this as a reasonable way to gather more information before committing either direction.
Genuinely unresolved: whether a second stone, or persistence of the same urate level despite lifestyle change, should be treated as equivalent to a first gout flare for the purposes of starting ULT. The rheumatologist would treat either as sufficient; the nephrologist would want to see it happen before deciding, still doubtful the number alone ever becomes the reason. That question was left open, to be revisited at the three-month follow-up rather than settled today.